Immunocore’s (IMCR) Buy Rating Reiterated at HC Wainwright

Immunocore (NASDAQ:IMCR)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $100.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 212.30% from the stock’s current price.

Several other analysts have also commented on the company. Needham & Company LLC decreased their price objective on Immunocore from $81.00 to $78.00 and set a “buy” rating for the company in a report on Tuesday, September 17th. Barclays dropped their price target on Immunocore from $92.00 to $66.00 and set an “overweight” rating on the stock in a research note on Friday, August 9th. Guggenheim lowered shares of Immunocore from a “buy” rating to a “neutral” rating in a research report on Monday, October 7th. UBS Group assumed coverage on shares of Immunocore in a research report on Thursday. They set a “sell” rating and a $24.00 target price on the stock. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $89.00 price target (up previously from $87.00) on shares of Immunocore in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $75.17.

Immunocore Trading Down 3.9 %

IMCR opened at $32.02 on Thursday. The company has a current ratio of 5.17, a quick ratio of 5.15 and a debt-to-equity ratio of 1.31. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -26.25 and a beta of 0.72. Immunocore has a 12 month low of $29.72 and a 12 month high of $76.98. The stock has a fifty day moving average price of $33.58 and a 200-day moving average price of $41.47.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.25. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. The business had revenue of $75.40 million during the quarter, compared to analyst estimates of $74.58 million. During the same period in the prior year, the firm posted ($0.37) earnings per share. The company’s quarterly revenue was up 26.2% on a year-over-year basis. As a group, equities research analysts anticipate that Immunocore will post -1.67 earnings per share for the current fiscal year.

Institutional Trading of Immunocore

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC lifted its holdings in Immunocore by 1,867.3% in the second quarter. SG Americas Securities LLC now owns 160,358 shares of the company’s stock valued at $5,435,000 after acquiring an additional 152,207 shares during the period. Candriam S.C.A. boosted its holdings in Immunocore by 65.8% during the second quarter. Candriam S.C.A. now owns 313,423 shares of the company’s stock worth $10,621,000 after buying an additional 124,417 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in Immunocore during the second quarter worth $3,686,000. Janus Henderson Group PLC grew its position in Immunocore by 45.8% during the first quarter. Janus Henderson Group PLC now owns 257,080 shares of the company’s stock valued at $16,711,000 after buying an additional 80,748 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Immunocore by 16.2% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 397,463 shares of the company’s stock valued at $13,470,000 after buying an additional 55,463 shares in the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.